Recent Analysts’ Ratings Updates for Eli Lilly and Company (LLY)

A number of firms have modified their ratings and price targets on shares of Eli Lilly and Company (NYSE: LLY) recently:

• 1/14/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by analysts at BMO Capital Markets.
• 1/6/2026 – Eli Lilly and Company is now covered by analysts at UBS Group AG. They set a “buy” rating and a $1,250.00 price target on the stock.
• 1/5/2026 – Eli Lilly and Company was given a new $1,234.00 price target on by analysts at Leerink Partners.
• 1/1/2026 – Eli Lilly and Company was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 12/22/2025 – Eli Lilly and Company had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/19/2025 – Eli Lilly and Company had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein.
• 12/18/2025 – Eli Lilly and Company had its “outperform” rating reaffirmed by analysts at Leerink Partners.
• 12/18/2025 – Eli Lilly and Company had its “neutral” rating reaffirmed by analysts at UBS Group AG.
• 12/17/2025 – Eli Lilly and Company had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $1,000.00 to $1,200.00. They now have a “buy” rating on the stock.
• 12/16/2025 – Eli Lilly and Company was given a new $1,230.00 price target on by analysts at Daiwa Capital Markets. They now have a “buy” rating on the stock.
• 12/16/2025 – Eli Lilly and Company was upgraded by analysts at Daiwa America from a “hold” rating to a “strong-buy” rating.
• 12/15/2025 – Eli Lilly and Company had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Eli Lilly and Company had its price target raised by analysts at The Goldman Sachs Group, Inc. from $951.00 to $1,145.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Eli Lilly and Company had its price target lowered by analysts at Bank of America Corporation from $1,286.00 to $1,268.00. They now have a “buy” rating on the stock.
• 12/10/2025 – Eli Lilly and Company had its “hold” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $1,070.00 price target on the stock.
• 12/10/2025 – Eli Lilly and Company had its price target raised by analysts at Wells Fargo & Company from $1,100.00 to $1,200.00. They now have an “overweight” rating on the stock.
• 12/9/2025 – Eli Lilly and Company had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Eli Lilly and Company had its price target raised by analysts at The Goldman Sachs Group, Inc. from $951.00 to $1,145.00. They now have a “buy” rating on the stock.
• 12/4/2025 – Eli Lilly and Company was given a new $1,200.00 price target on by analysts at BMO Capital Markets.
• 12/3/2025 – Eli Lilly and Company was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b-)” rating.
• 12/3/2025 – Eli Lilly and Company had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $1,163.00 price target on the stock.
• 12/3/2025 – Eli Lilly and Company had its price target raised by analysts at Wolfe Research from $1,050.00 to $1,250.00. They now have an “outperform” rating on the stock.
• 12/2/2025 – Eli Lilly and Company had its price target raised by analysts at BMO Capital Markets to $1,100.00. They now have an “outperform” rating on the stock.
• 12/2/2025 – Eli Lilly and Company had its price target raised by analysts at Berenberg Bank from $830.00 to $950.00. They now have a “hold” rating on the stock.
• 12/1/2025 – Eli Lilly and Company was given a new $1,286.00 price target on by analysts at National Bankshares, Inc..
• 12/1/2025 – Eli Lilly and Company had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 11/24/2025 – Eli Lilly and Company had its price target raised by analysts at Sanford C. Bernstein from $1,100.00 to $1,300.00. They now have an “outperform” rating on the stock.
• 11/24/2025 – Eli Lilly and Company had its price target raised by analysts at Morgan Stanley from $1,171.00 to $1,290.00. They now have an “overweight” rating on the stock.
• 11/19/2025 – Eli Lilly and Company had its price target raised by analysts at Truist Financial Corporation from $1,038.00 to $1,182.00. They now have a “buy” rating on the stock.
• 11/18/2025 – Eli Lilly and Company had its price target raised by analysts at JPMorgan Chase & Co. from $1,050.00 to $1,150.00. They now have an “overweight” rating on the stock.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.